Wockhardt Limited
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
What Wockhardt files
- Others57
- Updates31
- Board Meeting9
- Investor Meet6
- Important4
- PPTs3
Wockhardt launched its Antibiotic Academy, a key initiative to tackle multidrug resistance. This platform fosters scientific dialogue and education for medical professionals, aiming to improve patient outcomes and strengthen the company's position in the critical fight against superbugs.
Wockhardt reported strong Q1 FY27 results: PAT Rs. 107 Cr, revenue up 26% to Rs. 929 Cr, EBITDA up 86%. Biotech operations surged 112%. US FDA approved Zaynich for cUTI, a landmark for an India-discovered drug. Miqnaf® also launched in India.
Wockhardt received U.S. FDA approval for ZAYNICH™, a novel intravenous antibiotic for complicated urinary tract infections. This marks a historic milestone as the first New Chemical Entity fully developed by an Indian pharma company to receive FDA approval.
Wockhardt secures Indian market authorization for its breakthrough antibiotic, ZAYNICH®, treating complicated urinary tract infections. This first-in-class drug demonstrated superior efficacy in trials, targeting critical resistant infections.
Wockhardt reported a positive Q4 PBT of ₹189 Cr and full-year PBT of ₹238 Cr. Q4 revenue grew 30% to ₹965 Cr, while full-year revenue hit ₹3,373 Cr. Biotech operations soared 126% in Q4. Novel antibiotic Zaynich progressed with EMA accelerated assessment, and Miqnaf launched in India.